Paper Details

  1. Home
  2. Paper Details

Folate conjugated nanomedicines for selective inhibition of mTOR signaling in polycystic kidneys at clinically relevant doses.

Author: BaruiAyan K, MohieldinAshraf M, NauliSurya M, PalaRajasekharreddy, ZhouJing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Rapamycin is a drug that has been shown to be very effective in treating polycystic kidney disease (PKD) in rodents. However, it is not as effective in clinical trials because of its side effects. This study describes new nanoparticles that specifically target the kidneys. These nanoparticles are able to deliver rapamycin and an antioxidant directly to the kidneys, making the treatment more effective and reducing the side effects. This new approach has the potential to improve the treatment of PKD and other kidney diseases.
Paper Details　
Original Abstract of the Article :
Although rapamycin is a very effective drug for rodents with polycystic kidney disease (PKD), it is not encouraging in the clinical trials due to the suboptimal dosages compelled by the off-target side effects. We here report the generation, characterization, specificity, functionality, pharmacokine...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.biomaterials.2023.122329

データ提供：米国国立医学図書館（NLM）

Targeting Polycystic Kidneys: A Nanomedicine Approach

This study explores a novel nanomedicine approach for selectively delivering rapamycin, an mTOR inhibitor, to polycystic kidneys (PKD). Researchers developed folate-conjugated nanoparticles (NPs) that target PKD and deliver both rapamycin and the antioxidant 4-hydroxy-TEMPO. The study demonstrates that these NPs enhance the efficacy and tolerability of rapamycin, reducing off-target side effects and improving treatment outcomes in PKD mice. This research holds promise for developing more effective and targeted therapies for PKD.

Nanotechnology: A Precision Tool for PKD Treatment

The study reveals the potential of nanotechnology to improve the efficacy and safety of rapamycin treatment for PKD. The folate-conjugated NPs specifically target PKD, allowing for more precise drug delivery and reduced systemic exposure to rapamycin. This targeted approach not only improves treatment outcomes but also minimizes off-target side effects, potentially enhancing patient tolerability and quality of life.

A New Era of Nanomedicine for Chronic Kidney Disease

This research is like a desert spring, offering a promising new approach to managing PKD. The development of folate-conjugated NPs represents a significant advancement in nanomedicine, opening up new possibilities for treating chronic kidney diseases. The findings suggest that this targeted delivery approach could revolutionize PKD treatment, leading to more effective therapies and improved outcomes for patients.

Dr.Camel's Conclusion

This research is like a caravan of camels, carrying hope and innovation across the desert landscape of PKD. The development of folate-conjugated NPs offers a promising new approach to targeting PKD and improving treatment outcomes.

Date :
  1. Date Completed 2023-11-07
  2. Date Revised 2023-11-07
Further Info :

Pubmed ID

37722182

DOI: Digital Object Identifier

10.1016/j.biomaterials.2023.122329

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.